Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use

A method of screening a number of compounds with respect to their capability to inhibit the formation of a complex between 4RTR and N—AcPGP, screening occurring by means of an assay comprising a competition reaction between i) a compound A to be assayed and ii) a compound B comprising 4RTR and capable of binding N—AcPGP having an equilibrium constant K of 5·10−5 M−1 or lower, compound A and compound B being in competition for the binding to a Pro-Gly-Pro (PGP)—comprising compound C, with which the compound B is able to complex, having an equilibrium constant K of 5·10−5 M−1 or lower, and wherein a thus assayed compound A is selected having an equilibrium constant K for the reaction between compound A and the PGP-comprising compound C of 10−4 M−1 or lower.